XenoPort Announces Initiation Of A Phase 2b Clinical Trial Of Arbaclofen Placarbil In Patients With Gastroesophageal Reflux Disease

Posted in October 21, 2009 ¬ 1:00 pmh.adminComments Off

XenoPort, Inc. (Nasdaq:XNPT) announced today that it has initiated a Phase 2b clinical trial of arbaclofen placarbil (AP), also known as XP19986, in patients with gastroesophageal reflux disease (GERD) who remain symptomatic despite treatment with a proton pump inhibitor (PPI)…

Drugs

You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.